Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Key facts
- Where
- Fremont, Glendale, Indianapolis, Miami, Portsmouth, Rochester, San Antonio, Spokane, Webster, and Wilmington, United StatesSee the 10 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07362017, who can take part
Where in United States
- FremontFremont, United StatesTaking people
- GlendaleGlendale, United StatesTaking people
- IndianapolisIndianapolis, United StatesTaking people
- MiamiMiami, United StatesTaking people
- PortsmouthPortsmouth, United StatesTaking people
- RochesterRochester, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- SpokaneSpokane, United StatesTaking people
- WebsterWebster, United StatesTaking people
- WilmingtonWilmington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vanda Pharmaceuticals
- Trial code
- NCT07362017
- Record updated
- 22 September 2026
- Original description
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasisRead full original descriptionShow less
A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
Inclusion: Male and female subjects aged 18-65 years, inclusive; BMI >18 and <40; Minimum affected BSA of 10%; PASI score ≥ 12; PGA ≥ 3; Diagnosed with moderate-to-severe plaque psoriasis.
Exclusion: History of an allergic reaction or known and/or significant sensitivity to study drug; Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis.